Zastosowanie skojarzonej terapii wziewnej w leczeniu chorych na astmę i przewlekłą obturacyjną chorobę płuc Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2020
Słowa kluczowe:
astma, POChP, terapia skojarzona, terapia wziewna, compliance
##plugins.themes.bootstrap3.article.main##
Abstrakt
Wyniki badań klinicznych wykazały, że terapia skojarzona – wziewny glikokortykosteroid plus długo działający β2-mimetyk – pozwala uzyskać lepszą kontrolę astmy i przewlekłej obturacyjnej choroby płuc, zmniejszając liczbę zaostrzeń. Mocne dowody naukowe przemawiają za stosowaniem obu leków w jednym inhalatorze, bowiem wykazują one komplementarne działanie kliniczne i synergizm na poziomie molekularnym.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Górska , K., & Korczyński , P. (2020). Zastosowanie skojarzonej terapii wziewnej w leczeniu chorych na astmę i przewlekłą obturacyjną chorobę płuc . Medycyna Faktów , 13(3(48), 358-365. https://doi.org/10.24292/01.MF.0320.11
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2020.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2020.
3. Hagedorn C, Kässner F, Banik N et al. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD. Respir Med. 2013; 107: 542-9.
4. Laforest L, Denis F, Van Ganse E et al. Correlates of adherence to respiratory drugs in COPD patients. Prim Care Respir J. 2010; 19: 148-54.
5. Weinberg EG, Naya I. Treatment preferences of adolescent patients with asthma. Pediatr Allergy Immunol. 2000; 11: 49-55.
6. Li H-T, Zhang T-T, Zhou H et al. Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma. Respiration. 2007; 74: 33-43.
7. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170: 836-44.
8. Toy EL, Beaulieu NU, McHale JM et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011; 105: 435-41.
9. Coutts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child. 1992; 67: 332-3.
10. Winnicki M, Basiński K, Szyndler A et al. Jak poprawić stopień przestrzegania zaleceń terapeutycznych i jakość współpracy lekarz–pacjent. Choroby Serca i Naczyń. 2016; 13: 194-202.
11. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am. 2005; 25: 107-30.
12. Jankowska-Polańska B, Uchmanowicz I. Stosowanie się do zaleceń terapeutycznych w niewydolności serca. Choroby Serca i Naczyń. 2016; 13: 227-34.
13. Ágh T, Inotai A, Mészáros Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011; 82: 328-34.
14. Shapiro G, Lumry W, Wolfe J et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med. 2000; 161: 527-34.
15. Kavuru M, Melamed J, Gross G et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000; 105: 1108-16.
16. Nelson HS, Busse WW, Kerwin E et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000; 106: 1088-95.
17. Pearlman DS, Stricker W, Weinstein S et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol. 1999; 82: 257-65.
18. Aubier M, Pieters WR, Schlösser NJ et al. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med. 1999; 93: 876-84.
19. O’Connor RD, Rosenzweig JRC, Stanford RH et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann Allergy Asthma Immunol. 2005; 95: 535-40.
20. Chan J, Hui RL, Spence MM. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids. J Manag Care Pharm. 2007; 13: 21-7.
21. Stoloff SW, Stempel DA, Meyer J et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004; 113: 245-51.
22. Elkout H, McLay JS, Simpson CR et al. A retrospective observational study comparing rescue medication use in children on combined versus separate long-acting beta-agonists and corticosteroids. Arch Dis Child. 2010; 95: 817-21.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2020.
3. Hagedorn C, Kässner F, Banik N et al. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD. Respir Med. 2013; 107: 542-9.
4. Laforest L, Denis F, Van Ganse E et al. Correlates of adherence to respiratory drugs in COPD patients. Prim Care Respir J. 2010; 19: 148-54.
5. Weinberg EG, Naya I. Treatment preferences of adolescent patients with asthma. Pediatr Allergy Immunol. 2000; 11: 49-55.
6. Li H-T, Zhang T-T, Zhou H et al. Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma. Respiration. 2007; 74: 33-43.
7. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170: 836-44.
8. Toy EL, Beaulieu NU, McHale JM et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011; 105: 435-41.
9. Coutts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child. 1992; 67: 332-3.
10. Winnicki M, Basiński K, Szyndler A et al. Jak poprawić stopień przestrzegania zaleceń terapeutycznych i jakość współpracy lekarz–pacjent. Choroby Serca i Naczyń. 2016; 13: 194-202.
11. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am. 2005; 25: 107-30.
12. Jankowska-Polańska B, Uchmanowicz I. Stosowanie się do zaleceń terapeutycznych w niewydolności serca. Choroby Serca i Naczyń. 2016; 13: 227-34.
13. Ágh T, Inotai A, Mészáros Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011; 82: 328-34.
14. Shapiro G, Lumry W, Wolfe J et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med. 2000; 161: 527-34.
15. Kavuru M, Melamed J, Gross G et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000; 105: 1108-16.
16. Nelson HS, Busse WW, Kerwin E et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000; 106: 1088-95.
17. Pearlman DS, Stricker W, Weinstein S et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol. 1999; 82: 257-65.
18. Aubier M, Pieters WR, Schlösser NJ et al. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med. 1999; 93: 876-84.
19. O’Connor RD, Rosenzweig JRC, Stanford RH et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann Allergy Asthma Immunol. 2005; 95: 535-40.
20. Chan J, Hui RL, Spence MM. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids. J Manag Care Pharm. 2007; 13: 21-7.
21. Stoloff SW, Stempel DA, Meyer J et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004; 113: 245-51.
22. Elkout H, McLay JS, Simpson CR et al. A retrospective observational study comparing rescue medication use in children on combined versus separate long-acting beta-agonists and corticosteroids. Arch Dis Child. 2010; 95: 817-21.